GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » EV-to-FCF

Ablynx NV (XBRU:ABLXS) EV-to-FCF : -0.02 (As of Sep. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Ablynx NV EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ablynx NV's Enterprise Value is €0.97 Mil. Ablynx NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2017 was €-60.65 Mil. Therefore, Ablynx NV's EV-to-FCF for today is -0.02.

The historical rank and industry rank for Ablynx NV's EV-to-FCF or its related term are showing as below:

XBRU:ABLXS's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 8.225
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-21), Ablynx NV's stock price is €0.00. Ablynx NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was €0.000. Therefore, Ablynx NV's PE Ratio for today is N/A.


Ablynx NV EV-to-FCF Historical Data

The historical data trend for Ablynx NV's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV EV-to-FCF Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ablynx NV's EV-to-FCF

For the Biotechnology subindustry, Ablynx NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Ablynx NV's EV-to-FCF falls into.



Ablynx NV EV-to-FCF Calculation

Ablynx NV's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.971/-60.652
=-0.02

Ablynx NV's current Enterprise Value is €0.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ablynx NV's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2017 was €-60.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV  (XBRU:ABLXS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ablynx NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Ablynx NV's share price for today is €0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ablynx NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Ablynx NV EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Ablynx NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV Headlines

No Headlines